Target Validation Information
TTD ID	T15000
Target Name	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
Type of Target	Successful
Drug Potency against Target	Tremelimumab	Drug Info	IC50 = 0.5~0.65 nM
Action against Disease Model	Tremelimumab	Drug Info	Tremelim uMab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Tremelim uMab enhanced the proliferative response of T effector cells (Teff) upon TCR stimulation, and abrogated Treg suppressive ability. In the presence of tremelim uMab, frequencies of IL-2-secreting CD4(+) T cells and IFN-|??secreting CD4(+) and CD8(+) T cells were increased in response to polyclonal activation and t uMor antigens.	[1]
References
REF 1	Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol. 2011 Jan;138(1):85-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.